• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

FDA Authorizes ArteraAI Prostate: The First AI-Powered Tool for Prostate Cancer Prognosis

by Syed Hamza Sohail 08/14/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
FDA Authorizes ArteraAI Prostate: The First AI-Powered Tool for Prostate Cancer Prognosis

What You Should Know:

–  Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

– ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical Device (SaMD).

Artera Secures FDA De Novo Authorization for AI-Powered Prostate Cancer Diagnostic Platform

Artera, a global leader in precision oncology, is redefining cancer care through its multimodal artificial intelligence (MMAI) platform, which integrates digitized biopsy images with patient clinical data to assess cancer aggressiveness and predict therapy benefit. Validated across multiple Phase 3 randomized trials and various cancer types, Artera’s MMAI technology is deployed globally through a suite of innovative products.

The company’s flagship ArteraAI Prostate Test—commercially available in the U.S. as a laboratory-developed test and internationally via distribution partners—is the first test to provide both prognostic and predictive insights for prostate cancer, enabling clinicians and patients to make timely, evidence-based treatment decisions.

Regulatory Milestone and Expanded Capabilities

Artera has earned FDA De Novo authorization for its ArteraAI Prostate medical device software, establishing a new product code category for future AI-powered digital pathology risk-stratification tools. This authorization, paired with UKCA certification for the ArteraAI Breast Test, ArteraAI Prostate Biopsy Assay, and ArteraAI Prostate, extends the platform’s reach across key global markets.

  • Point-of-Diagnosis Integration – Enables qualified pathology labs in the U.S. to deliver actionable prostate cancer insights at the time of diagnosis, reducing delays in care.
  • Predetermined Change Control Plan – Allows platform expansion to additional digital pathology scanners without requiring new 510(k) submissions.
  • Breakthrough Device Designation – Preceded the De Novo authorization, underscoring the innovation’s clinical significance.

“This is a defining moment for AI in cancer care,” said Andre Esteva, CEO and co-founder of Artera. “The FDA’s decision validates our vision to deliver AI-guided tools that enable data-backed, tailored treatments for each patient—enhancing confidence throughout the cancer journey and ultimately saving more lives.”

With its latest regulatory clearance, Artera is positioned to scale its MMAI-powered portfolio, accelerating the adoption of precision oncology solutions and advancing the standard of personalized cancer care worldwide.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |